Brief: Hikma Pharmaceuticals Reaches Licensing Agreement With Celltrion
Dec 19 (Reuters) - Hikma Pharmaceuticals:
* REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD
BIOSIMILAR
PRODUCT IN MIDDLE EAST AND NORTH AFRICA
* LICENSING AGREEMENT FOR BIOSIMILAR MONOCLONAL ANTIBODY
(MAB) IN
ONCOLOGY TO BE GRANTED EUROPEAN MARKETING AUTHORISATION,
TRUXIMA
Source text for Eikon: ID:nRSS6681Za
Further company coverage: 068270.KQ
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap